antibodies against cd44  (Bio-Rad)

Journal: ACS applied materials & interfaces

Article Title: Dual-Targeting Strategy to Repurpose Cetuximab with HFn Nanoconjugates for Immunotherapy of Triple-Negative Breast Cancer.

doi: 10.1021/acsami.5c06626

Figure Lengend Snippet: Figure 3. The HFn−CTX nanoconjugate and the HFn nanoparticles show similar uptake kinetics in GBM cells. (A) Representative images of U-87 MG cells incubated with double-labeled HFn−CTX or labeled HFn (0.1 mg mL−1 each) for 2, 5, 25, 30, 60, and 120 min. HFn−AF647 is depicted in red, CTX in magenta, and CTX detected with anti-human-AF488 in green. The plasma membrane (PM) was stained with CD44 (yellow), and nuclei were stained with Hoechst (blue). Scale bar, 100 μm. (B) Manders’ coefficient analysis on the HFn−CTX nanoconjugate and HFn nanoparticles. The bar graph shows tM1 (CTX-AF488 signal vs HFn−AF647 signal, blue bars) and tM2 (HFn−AF647 signal vs CTX-AF488 signal, red bars) at the indicated time points.

Article Snippet: Primary antibodies: CD44 (clone IM7; Bio-Rad, MCA4703), CD31/PECAM-1 (Biotechne, AF3628), CD71 (clone D7G9X, Cell Signaling, 13113),32,33 EGFR (clone D38B1, Cell Signaling, 4267), βActin (clone D6A8, Cell Signaling, 8457), EGFR (clone 528, Merck, GR01), CD71 (clone MEM-75, Invitrogen, MA1-19137), and Ferritin Heavy Chain (clone EPR3005Y, Abcam, ab75972).

Techniques: Incubation, Labeling, Clinical Proteomics, Membrane, Staining